about
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapyClinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.Development and Validation of a Questionnaire for the Assessment of Pelvic Floor Disorders and Their Risk Factors During Pregnancy and Post PartumNeurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis.IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria?A beneficial role for immunoglobulin E in host defense against honeybee venom.Mast cells promote homeostasis by limiting endothelin-1-induced toxicity.Mast cells can enhance resistance to snake and honeybee venoms.Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses.Acquired cold urticaria symptoms can be safely prevented by ebastine.Successful treatment of solar urticaria with anti-immunoglobulin E therapy.Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in miceMast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokinesThe status quo and quo vadis of mast cells.Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial.Mast cells rescue implantation defects caused by c-kit deficiency.Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?Mast cells--key effector cells in immune responses.Mast cells in the promotion and limitation of chronic inflammation.Mast cell functions in the innate skin immune system.Mast cells: makers and breakers of allergic inflammation.The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations.Innate immunity and allergy in the skin.Chronic pruritus--pathogenesis, clinical aspects and treatment.Rupatadine for the treatment of allergic rhinitis and urticaria.Pruritus: an overview of current concepts.Pathophysiology of itch and new treatments.Miltefosine: a novel treatment option for mast cell-mediated diseases.Role and relevance of mast cells in fungal infectionsOmalizumab in chronic urticaria.The role of interleukin-1 in allergy-related disorders.Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians.Magistral formulations and pruritus therapy - What is established, what is confirmed, what is new?Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria.The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.Omalizumab may not inhibit mast cell and basophil activation in vitro.EADV European Prurigo Project: Expert Consensus on the Definition, Classification and Terminology of Chronic Prurigo.Comparison and Interpretability of the available Urticaria Activity Scores.Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence.T cell killing by tolerogenic dendritic cells protects mice from allergy
P50
Q28264284-1D6FA97E-82D7-4D81-9249-FBFDEC8A1EE8Q33588223-BD2EB14A-50E1-48CA-8299-C7C012D0B608Q33606791-44F0B1D8-DD68-420A-A078-7585B592202FQ33866102-34FFFDA7-5CB3-4F13-9FCC-254F64B63861Q33885869-B0FA6DBC-0728-4F44-82AF-0C44E4F7ED4AQ34182028-68B2383A-B5EA-48E2-BAFF-3E3F757A529EQ34367607-C2EFE912-54C2-4777-907F-A2503E0CFFD5Q34551900-700F22D6-4920-4F16-8F74-B3B42B19E8EFQ34570242-BE3DF1BA-1AAC-4007-AE40-DAFD1DBE3221Q34694547-496C0533-8816-4E6F-B101-D7BC1A4B499BQ34858119-8B987D6D-E2AB-4ED0-9C5E-E933356B8E56Q35370039-064661D5-A26D-4746-BA23-714A50DEA5DEQ35921836-0BD3DF3E-17A2-4010-B5C1-49A8464D8E2AQ36307960-FD5533AF-5728-4286-8076-FD6F4407E223Q36359983-95A60F53-3C4B-4699-BF27-9CB089ACD539Q36586548-9E8AD800-85C4-4A4D-BD3B-FECFA57FE30AQ36604434-F0FC01F3-74A7-4969-9C94-1BADCF46DDC9Q36776875-C86DC828-C739-475D-AE64-940808113DDCQ36819950-3806823A-9CD8-40CC-90C7-8FED0DF39A2CQ37136142-FD46924B-A4C5-479E-A442-E7B6FE0D1EA6Q37529040-27F46145-6FF4-4182-9F2D-D4F946BC76A8Q37605896-E53DBC79-47F3-4836-890A-0E13791D9252Q37614641-77C60B2C-0578-4764-A34D-2385163020DFQ37789400-DC11B853-366F-4434-A2B0-3FD144998D12Q37821491-1FC9721B-2BC1-4DE9-81DA-B4D1030000DBQ37830761-E7B30FEA-2207-4568-AB5B-29507529ECB0Q37902833-2966B3B9-0730-4F5C-92D7-2A99D38F5F74Q37989998-6CF047C0-7F7F-4C9D-80E3-51B1196DD0F3Q38019500-ECB96659-31C1-4C94-8666-F15488B30C87Q38024238-2E094777-85CD-46B4-86AD-3B88923FB7EBQ38034022-847F6524-DB69-48E8-A473-EE96C9300F37Q38131810-978D53DB-34DF-450C-9C4F-CBF36F759DCEQ38151975-BAD707A4-CF36-4EE9-998C-A02C0C34C9CAQ38217720-828710B9-EEBF-48F0-BDA0-0781F293EAEFQ38221816-D87C7CB6-BBDC-489D-966D-C6C92E63111EQ38254504-87833E90-8756-4FFB-83E5-6B8CC444E832Q38600600-5718CE43-6C01-466A-8813-BC3D25F43427Q38620912-D0A6DCC9-A7A3-4797-B8BC-3025038836AAQ38656712-B1B70E1E-31C4-4686-AFC2-8125168C5017Q38732376-75A2BB82-B0C6-4099-8CA7-E4BA9B8119FE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Martin Metz
@ast
Martin Metz
@en
Martin Metz
@es
Martin Metz
@nl
Martin Metz
@sl
type
label
Martin Metz
@ast
Martin Metz
@en
Martin Metz
@es
Martin Metz
@nl
Martin Metz
@sl
prefLabel
Martin Metz
@ast
Martin Metz
@en
Martin Metz
@es
Martin Metz
@nl
Martin Metz
@sl
P1053
B-8799-2009
M-5237-2013
P106
P1153
7005788430
P21
P2798
P31
P3829
P496
0000-0002-4070-9976